To translate the molecular insights into a clinic-related setting, the pharmacological BCL2 antagonist venetoclax was studied as proof-of-concept, as it is (i) increasingly applied in patients, especially in situations of resistance against conventional chemotherapy [36, 37] and (ii) high BCL2 expression correlated to inferior treatment response in both B-ALL (p < 0.01) and AML (Fig. S9A, B) [38–40]. Here, BCL2 is linked to acute myeloid leukemia.